title: [Porphyrin metabolic disorders in the genesis of fetoplacental insufficiency in hyperandrogenism].
abstract: The association of a ratio of blood porphyrin fraction concentrations in pregnant women with hyperandrogenism (HA) with the osmoresistance of red blood cells and the microviscosity of their membranes was studied. A cohort examination was made in parallel groups of 64 pregnant women aged 20 to 30 years at 28-36 weeks gestation. The levels of dehydroepiandrosterone sulfate (DHEAS) and testosterone were measured. External cardiotocography, ultrasonography, and Doppler study were conducted. The blood concentrations of endogenous protoporphyrin (PP) and coproporphyrin (CP) were estimated by the spectral fluorescence technique. Erythrocytic membrane microviscosity was determined from the degree of pyrene eximeration, by measuring the fluorescence spectra; erythrocytic osmoresistance was ascertained by the procedure developed by N. L. Vasilevskaya. The pregnant women with placental insufficiency in the presence of HA were found to have an altered ratio of the concentrations of erythrocytic porphyrin fractions, which enhanced the microviscosity and resistance of red blood cell membranes, causing worse microcirculation. There was an inverse correlation between the level of DHEAS and the ratio of the concentrations of endogenous PP to CP. It is concluded that the development of placental insufficiency in pregnant women with HA is attended by the decreased ratio of PP to CP along with the higher microviscous characteristics of erythrocytic membranes and the lower amplitude of their osmoresistance, by increasing the lower osmoresistance range.
authors: N A
authors: NA
authors: Gabitova
authors: L A
authors: LA
authors: Agarkova
authors: V V
authors: VV
authors: Udut
authors: N G
authors: NG
authors: Belova
authors: R T
authors: RT
authors: Kuznetsova
authors: E G
authors: EG
authors: Ermolina
authors: V E
authors: VE
authors: Prokop'ev
authors: N A
authors: NA
authors: Burykhina
mesh_terms: D000328:Adult; D016022:Case-Control Studies; D019314:Dehydroepiandrosterone Sulfate / Q000097:blood; D003907:Dexamethasone / Q000008:administration & dosage / Q000627:therapeutic use; D004910:Erythrocyte Membrane / Q000378:metabolism; D005260:Female; D005865:Gestational Age; D006801:Humans; D017588:Hyperandrogenism / Q000097:blood / Q000150:complications* / Q000188:drug therapy / Q000378:metabolism / Q000503:physiopathology; D009996:Osmotic Fragility; D021041:Placental Circulation / Q000502:physiology*; D010927:Placental Insufficiency / Q000209:etiology* / Q000378:metabolism; D011166:Porphyrins / Q000378:metabolism*; D011247:Pregnancy; D013739:Testosterone / Q000097:blood; D055815:Young Adult
chemical_list: D011166:Porphyrins; D013739:Testosterone; D019314:Dehydroepiandrosterone Sulfate; D003907:Dexamethasone